EU to study potential vaccine for Lyme disease: Companies
EU officials have agreed to study an experimental vaccine against Lyme disease, the world's most common tick-borne illness, its developers said Friday.
The European Union has decided to investigate an experimental vaccine against Lyme disease, reported wire services. Pfizer and French-Swiss company Valneva announced Friday that their vaccine, called PF-07307405, demonstrated 70% efficacy in trials for people aged five and above. Despite a less than stellar trial result earlier in the year, the European Medicines Agency has approved the application for the treatment's approval, formally named PF-07307405.
The experimental vaccine aims to provide an additional layer of protection against Lyme disease, a tick-borne illness that affects over 14% of the global population, according to a 2022 research. Lyme disease can cause rashes, flu-like symptoms, and in some cases, neurological problems. Although rarely fatal, the disease's transmission rates could potentially grow due to climate change resulting in longer, drier summers.
Pfizer's chief vaccines officer, Annaliesa Anderson, expressed optimism about the potential of vaccination in combating this debilitating disease in a joint statement. Valneva's CEO, Thomas Lingelbach, acknowledged the European Medicines Agency's acceptance as a significant milestone, given that more than 200 million people reside in Lyme disease risk areas in Europe.
The European Medicines Agency's acceptance of the application for the vaccine treatment marks a crucial step forward, especially considering the high number of people living in Lyme disease risk areas across Europe.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — it may contain errors, so check the original before relying on it.
Also reported by 1 other outlet
- EU to study potential vaccine for Lyme disease: companies torontosun.com
